Mineralys Therapeutics (MLYS) Operating Expenses (2022 - 2026)

Mineralys Therapeutics has reported Operating Expenses for 5 years, with the latest figure at $45.3 million in Q1 2026.

• Quarterly Operating Expenses rose 2.01% year-over-year to $45.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $171.5 million (down 14.88% YoY) and the FY2025 annual result came in at $170.6 million, down 11.33% from the prior year.
• Operating Expenses advanced to $45.3 million in Q1 2026 per MLYS's latest filing, from $38.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $60.1 million in Q3 2024 and troughed at $6.5 million in Q2 2022.
• A 5-year average of $30.9 million and a median of $35.4 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses soared 253.94% in 2023, then tumbled 31.57% in 2025.
• Over 5 years, Operating Expenses stood at $10.0 million in 2022, then surged by 176.89% to $27.7 million in 2023, then jumped by 86.81% to $51.8 million in 2024, then dropped by 26.05% to $38.3 million in 2025, then rose by 18.44% to $45.3 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $45.3 million, $38.3 million, and $41.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.